Last reviewed · How we verify

NCT03614754

Sacral Neuromodulation and Pudendal Somatic Afferents

Status unknown Last updated 15 October 2019
What this trial tests

trial testing Somatosensory evoked potentials in Overactive Bladder, Non Obstructive Urinary Retention in 40 participants. Status unknown.

Timeline
1 August 2017
Primary endpoint
31 July 2022
31 July 2022

Quick facts

Lead sponsorUniversiteit Antwerpen
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 August 2017
Primary completion31 July 2022
Estimated completion31 July 2022
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universiteit Antwerpen — full company profile →

Who can join

18 and older, any sex, with Overactive Bladder, Non Obstructive Urinary Retention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sacral neuromodulation is a well-excepted minimally invasive procedure for the treatment of overactive bladder and non-obstructive urinary retention.A tined lead with 4 stimulation electrodes is placed through the third or fourth sacral foramen and stimulates sacral roots in its vicinity. Since the sacral roots are mixed nerves, it is currently still unknown which nerve fibers are stimulated (autonomic vs somatic, afferent vs efferent) and what the mechanism of action is. This study examines the involvement of pudendal somatic afferents by measuring somatosensory evoked potentials elicited by stimulation of the pudendal nerve.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Somatosensory evoked potentials

Trials testing the same drug.

Other Universiteit Antwerpen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03614754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing